ClinicalTrials.gg

Program

fluticasone furoate

Also written as “GW685698X”, “FF/UMEC/VI” and “Fluticasone furoate”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Perennial · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, led by 4 companies.

Furthest: phase 4, since Feb 14, 200797 company-led studies, 2 open or runningNext primary completion: Jan 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline942 open or runningphase 4since Feb 14, 2007Feb 8, 2005Jan 26, 2027phase 3 · NCT05757102
Novartis10 open or runningphase 3since Jan 17, 2011Jan 17, 2011none ahead
ORA10 open or runningphase 4since Feb 24, 2010Feb 24, 2010none ahead
Sandoz10 open or runningphase 3since Oct 15, 2025Oct 15, 2025none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since May 20, 2010.

  1. Mar 24, 2016Phase 4 study in AsthmaGlaxoSmithKline · NCT02730351 · 75 enrolled · United States, Canada
  2. Jul 15, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT02837380 · 16 enrolled · China
  3. Aug 31, 2016Phase 4 study in AsthmaGlaxoSmithKline · NCT02889809 · 477 enrolled · United States, Argentina, Poland and more
  4. Nov 30, 2017Phase 4 study in AsthmaGlaxoSmithKline · NCT03363191
  5. Dec 1, 2017Phase 3 study in AsthmaGlaxoSmithKline · NCT03376932
  6. Feb 2, 2018Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03467425 · 3,109 enrolled · Germany, Netherlands, Spain and more
  7. Mar 15, 20183 phase 4 studies in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03474081, NCT03478696, NCT03478683
  8. May 13, 2019Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03949842 · United States
  9. Jun 2, 2021Phase 3 study in AsthmaGlaxoSmithKline · NCT04937387 · 359 enrolled · China
  10. Jun 6, 2021Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT04923347 · 229 enrolled · India
  11. Sep 7, 2022Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT05535972 · 463 enrolled · China
  12. Feb 24, 2023Phase 3 study in AsthmaGlaxoSmithKline · NCT05757102 · 138 enrolled · United States, Argentina, Australia and more
  13. Apr 15, 2024Phase 4 study in AsthmaGlaxoSmithKline · NCT06372496 · 1,358 enrolled · United States, Argentina, Australia and more
  14. Oct 15, 2025Sandoz’s first study: phase 3 study in RespiratoryNew to SandozSandoz · NCT07223294

Ahead

  1. Jan 26, 2027Primary completion: phase 3 study in AsthmaGlaxoSmithKline · NCT05757102

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The newest 60 of 97 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07223294Respiratory3WithdrawnSandozApr 21, 20260
NCT06372496Asthma · United States, Argentina, Australia and more4Active, not recruitingGlaxoSmithKlineJul 28, 20251,358
NCT05757102Asthma · United States, Argentina, Australia and more3Active, not recruitingGlaxoSmithKlineJan 26, 2027138
NCT05535972Pulmonary Disease, Chronic Obstructive · China4CompletedGlaxoSmithKlineSep 25, 2023463
NCT04923347Pulmonary Disease, Chronic Obstructive · India4CompletedGlaxoSmithKlineMar 14, 2024229
NCT04937387Asthma · China3CompletedGlaxoSmithKlineAug 5, 2024359
NCT03949842Pulmonary Disease, Chronic Obstructive · United States4WithdrawnGlaxoSmithKlineNov 30, 20220
NCT03478696Pulmonary Disease, Chronic Obstructive · United States, Czechia, Germany4CompletedGlaxoSmithKlineMar 18, 2019732
NCT03478683Pulmonary Disease, Chronic Obstructive · United States, Czechia, Germany and more4CompletedGlaxoSmithKlineMar 14, 2019729
NCT03474081Pulmonary Disease, Chronic Obstructive · United States, Poland, Russian Federation4CompletedGlaxoSmithKlineJul 17, 2019800
NCT03467425Pulmonary Disease, Chronic Obstructive · Germany, Netherlands, Spain and more4CompletedGlaxoSmithKlineOct 10, 20193,109
NCT03376932Asthma3WithdrawnGlaxoSmithKlineFeb 3, 20210
NCT03363191Asthma4WithdrawnGlaxoSmithKlineMay 29, 20190
NCT02889809Asthma · United States, Argentina, Poland and more4CompletedGlaxoSmithKlineApr 9, 2021477
NCT02837380Pulmonary Disease, Chronic Obstructive · China1CompletedGlaxoSmithKlineNov 201616
NCT02730351Asthma · United States, Canada4CompletedGlaxoSmithKlineFeb 3, 201775
NCT02712047Asthma · New Zealand2CompletedGlaxoSmithKlineFeb 21, 201728
NCT02666287Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedGlaxoSmithKlineJun 3, 201648
NCT02573870Pulmonary Disease, Chronic Obstructive · United States2CompletedGlaxoSmithKlineJul 5, 201663
NCT02502734Asthma · Denmark3CompletedGlaxoSmithKlineDec 21, 201560
NCT02483975Asthma · United States, South Africa3CompletedGlaxoSmithKlineJun 20, 2016111
NCT02446418Asthma · France, Germany3CompletedGlaxoSmithKlineJul 20, 2017423
NCT02164513Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineJul 17, 201710,355
NCT02105974Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Germany and more3CompletedGlaxoSmithKlineJul 8, 20151,621
NCT02094937Asthma · Japan3CompletedGlaxoSmithKlineAug 28, 2015430
NCT02064504Pulmonary Disease, Chronic Obstructive · Australia1CompletedGlaxoSmithKlineMay 20, 201448
NCT01962467Rhinitis · Australia1CompletedGlaxoSmithKlineFeb 27, 201430
NCT01957150Pulmonary Disease, Chronic Obstructive · United States, Canada, Germany and more4CompletedGlaxoSmithKlineMar 26, 2018283
NCT01808339Asthma · Australia2CompletedGlaxoSmithKlineMar 201428
NCT01691547Pulmonary Disease, Chronic Obstructive · United States1CompletedGlaxoSmithKlineMar 8, 201344
NCT01686633Asthma · United States, Argentina, Chile and more3CompletedGlaxoSmithKlineOct 1, 20131,040
NCT01691885Pulmonary Disease, Chronic Obstructive · United Kingdom3CompletedGlaxoSmithKlineJul 201445
NCT01630135Rhinitis, Allergic, Perennial · Japan3CompletedGlaxoSmithKlineAug 2012261
NCT01627327Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more3CompletedGlaxoSmithKlineDec 1, 2012623
NCT01622231Rhinitis · Japan3CompletedGlaxoSmithKlineNov 201261
NCT01563029Asthma · United States, Bulgaria, Georgia and more2CompletedGlaxoSmithKlineSep 24, 2014597
NCT01498679Asthma · China, Korea, Republic of, Philippines3CompletedGlaxoSmithKlineJul 2013311
NCT01498653Asthma · China, Korea, Republic of, Philippines3CompletedGlaxoSmithKlineFeb 2013313
NCT01499446Asthma · Brazil, Bulgaria, Chile and more2CompletedGlaxoSmithKlineMar 2004669
NCT01485445Asthma · Germany1CompletedGlaxoSmithKlineMar 12, 201230
NCT01436110Asthma · United States, Mexico, Netherlands and more3CompletedGlaxoSmithKlineSep 2012351
NCT01436071Asthma · United States, Mexico, Peru and more3CompletedGlaxoSmithKlineJun 2012248
NCT01435902Asthma3WithdrawnGlaxoSmithKlineAug 20120
NCT01431950Asthma · United States, Argentina, Chile and more3CompletedGlaxoSmithKlineOct 2012238
NCT01395888Pulmonary Disease, Chronic Obstructive · Argentina, France, Germany and more3CompletedGlaxoSmithKlineAug 1, 2012260
NCT01342913Pulmonary Disease, Chronic Obstructive · Belgium, France, Germany and more3CompletedGlaxoSmithKlineOct 1, 2011528
NCT01323634Pulmonary Disease, Chronic Obstructive · United States, Czechia, Germany and more3CompletedGlaxoSmithKlineDec 14, 2011519
NCT01323621Pulmonary Disease, Chronic Obstructive · United States, Germany, Italy and more3CompletedGlaxoSmithKlineJan 1, 2012512
NCT01313676Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineJul 15, 201516,568
NCT01279057Rhinitis, Allergic, Seasonal · United States3CompletedNovartisFeb 8, 2011727
NCT01244984Asthma · Japan3CompletedGlaxoSmithKlineJan 2012243
NCT01332292Asthma · United States2CompletedGlaxoSmithKlineJan 201127
NCT01231464Rhinitis, Allergic, Perennial · China3CompletedGlaxoSmithKlineMay 2010365
NCT01213849Asthma · United Kingdom1CompletedGlaxoSmithKlineNov 25, 201024
NCT01165138Asthma · United States, Germany, Japan and more3CompletedGlaxoSmithKlineOct 1, 2011612
NCT01159912Asthma · United States, Belgium, Germany and more3CompletedGlaxoSmithKlineJan 1, 2012350
NCT01299558Asthma · Australia1CompletedGlaxoSmithKlineJul 15, 201016
NCT01147848Asthma · United States, Argentina, Chile and more3CompletedGlaxoSmithKlineJul 2011810
NCT01134042Asthma · United States, Germany, Japan and more3CompletedGlaxoSmithKlineOct 2011587
NCT01128595Asthma · Australia, New Zealand, Sweden2CompletedGlaxoSmithKlineMay 201127

How it is read

Names in the registry

  • “GW685698X”, 16 entries
  • “FF/UMEC/VI”, 9 entries
  • “Fluticasone furoate”, 8 entries
  • “FF”, 6 entries
  • “Fluticasone Furoate”, 5 entries

Codes read as this program: GW685698.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.